Scott N. Cullison
Corporate Officer/Principal chez XENETIC BIOSCIENCES, INC.
Profil
Scott N.
Cullison is currently the Vice President of Business Development at Xenetic Biosciences, Inc. He previously worked as the Director of Business & Commercial Development at Targacept, Inc. from 2012 to 2014.
From 2015 to 2018, he served as the VP of Commercial Planning & Program Management at Bellicum Pharmaceuticals, Inc. Additionally, he held the position of VP of Business Development & Commercial Planning at Peloton Therapeutics, Inc. Mr. Cullison holds an MBA from Wake Forest University and an undergraduate degree from the University of Arizona.
Postes actifs de Scott N. Cullison
| Sociétés | Poste | Début |
|---|---|---|
| XENETIC BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Scott N. Cullison
| Sociétés | Poste | Fin |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/11/2018 |
| PELOTON THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Corporate Officer/Principal | - |
Formation de Scott N. Cullison
| Wake Forest University | Masters Business Admin |
| University of Arizona | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XENETIC BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |